| Item Type | Name |
|
Academic Article
|
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms.
|
|
Concept
|
Survival Analysis
|
|
Academic Article
|
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.
|
|
Academic Article
|
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression.
|
|
Academic Article
|
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
|
|
Academic Article
|
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
|
|
Academic Article
|
Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy.
|
|
Academic Article
|
Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia.
|
|
Academic Article
|
Doxorubicin plus tumor necrosis factor alpha combination treatments in EL4-lymphoma-bearing C57BL/6 mice.
|
|
Academic Article
|
Prognostic significance of Tie-1 protein expression in patients with early chronic phase chronic myeloid leukemia.
|
|
Academic Article
|
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
|
|
Academic Article
|
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
|
|
Academic Article
|
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation.
|
|
Academic Article
|
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
|
|
Academic Article
|
New approaches in the treatment of myelofibrosis.
|
|
Academic Article
|
Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome.
|
|
Academic Article
|
Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia.
|
|
Academic Article
|
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
|
|
Academic Article
|
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.
|
|
Academic Article
|
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.
|
|
Academic Article
|
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
|
|
Academic Article
|
Hepatosplenic gamma-delta T-cell lymphoma: clinicopathological features and treatment.
|
|
Academic Article
|
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors.
|
|
Academic Article
|
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia.
|
|
Academic Article
|
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
|
|
Academic Article
|
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase.
|
|
Academic Article
|
Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
|
|
Academic Article
|
Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy.
|
|
Academic Article
|
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls.
|
|
Academic Article
|
Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis.
|
|
Academic Article
|
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.
|
|
Academic Article
|
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.
|
|
Academic Article
|
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.
|
|
Academic Article
|
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials.
|
|
Academic Article
|
Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).
|
|
Academic Article
|
Practical Measures of Clinical Benefit With Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I.
|
|
Academic Article
|
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
|
|
Academic Article
|
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.
|
|
Academic Article
|
Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.
|
|
Academic Article
|
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.
|
|
Academic Article
|
Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.
|
|
Academic Article
|
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial.
|
|
Academic Article
|
Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable.
|
|
Academic Article
|
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial.
|
|
Academic Article
|
Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era.
|
|
Academic Article
|
Phase II study of single-agent nivolumab in patients with myelofibrosis.
|
|
Academic Article
|
Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval.
|